FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing
→ Months after the UK’s cost-effectiveness agency NICE had a change of heart on its drug Rubraca — Clovis has announced that the FDA granted priority review for its application to expand the use of the drug to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer. The PDUFA date is May 15, 2020. Clovis’ shares $CLVS rose nearly 13.5% to $10.10 in Wednesday morning trading.
→ Colorado-based Arpeggio — whose technology reconstructs the biological network a drug affects and identifies the genes critical for the success or failure of a therapy — has closed a $3.2 million seed financing round, it said on Wednesday.
→ Cancer genomics company Personal Genome Diagnostics is partnering with Eisai to develop liquid biopsy biomarker discovery technology. “Utilizing digital technology, our history in drug development and PGDx’s liquid biopsy expertise, we expect this new solution will help address the complexities of developing new oncology drugs,” said Takashi Owa of Eisai’s Oncology Business Group.